Melatonin (MEL) and its use in circadian rhythm sleep-wake disorders: Recommendations of the French Medical and Research Sleep Society (SFRMS) - 12/01/21
Members of the MEL consensus group of the SFRMS1
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Highlights |
• | Immediate release melatonin is indicated for circadian rhythm disorders. |
• | The maximum chronobiotic effect is time dependent (4 to 6hours before sleep onset) and dose dependent (low dosages). |
• | Higher dosages half an hour before bedtime has a small chronobiotic effect and a soporific effect. |
• | For non-24-hour sleep/wake disorder, melatonin should be administered when the patient's circadian rhythm coincides with conventional sleep/wake schedules. |
• | Melatonin should be associated with sleep hygiene and cognitive behavior therapy. |
Abstract |
The French society of medical research on sleep (SFRMS) appointed a group of experts to conduct a consensus conference in order to study the indications and prescription status of exogenous melatonin (MEL). Eleven sleep physicians/researchers investigated in subgroups the use of MEL in different domains of healthcare in line with their subspecialties (circadian sleep/wake rhythm disorders, psychiatric disorders, neurological disorders, pediatric and neurodevelopmental disorders). In this article we present a summary of the main conclusions of the expert group on MEL therapy in circadian sleep/wake rhythm disorders such us delayed sleep-wake disorder, non-24-hour sleep wake rhythm disorder and jet lag.
Le texte complet de cet article est disponible en PDF.Keywords : French consensus, Melatonin, Delayed sleep phase, Non-24-hour, Jet lag
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?